Adverse Events, Radiation Exposure, and Reinterventions Following Transcatheter Pulmonary Valve Replacement

Goldstein, Bryan H.; Bergersen, Lisa; Armstrong, Aimee K.; Boe, Brian A.; El‐Said, Howaida; Porras, Diego; Shahanavaz, Shabana; Leahy, Ryan; Kreutzer, Jacqueline; Zampi, Jeffrey D.; Hainstock, Michael; Gudausky, Todd M.; Nicholson, George T.; Goodman, Andrea; Petit, Christopher J.

doi:10.1016/j.jacc.2019.11.042

Cited by 26 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Post-TOF repair SPVR carries a mortality risk of up to 1.2% and a risk of morbidity because of procedural complications. [19][20][21][22] Since 2010, we found 5.8% mortality in the SPVR group. At our institute, RVOT conduit replacement for obstruction carries an additional mortality risk compared with initial placement.…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Outcomes of Transcatheter Pulmonary Valve Replacement and Surgical Pulmonary Valve Replacement: A Cohort Analysis

Durongpisitkul¹,

Dangrungroj²,

Chungsomprasong³

et al. 2022

Journal of the Society for Cardiovascular Angiography & Int

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 85%

“…The immediate echocardiography measurement of the RVOT gradient was similar between groups: TPVR (15 mm Hg [11.3-22]) Q26 and SPVR (15 mm Hg [13][14][15][16][17][18][19][20]) (P ¼ .752). In the TPVR group, there were 62 (83.1%) patients with no PR and 5 (6.9%) patients with mild PR.…”

Section: Pv Function Immediately Postreplacement and At The 1-and 2-y...mentioning

confidence: 87%

Outcomes of Transcatheter Pulmonary Valve Replacement and Surgical Pulmonary Valve Replacement: A Cohort Analysis

Durongpisitkul¹,

Dangrungroj²,

Chungsomprasong³

et al. 2022

Journal of the Society for Cardiovascular Angiography & Int

View full text Add to dashboard Cite

“…As a result, only one case of type 1 fracture was observed. The efforts made to prevent and reduce the occurrence of fractures of hemodynamically important valves are likely to yield even better long-term outcomes than those documented in previous studies [ 5 , 6 , 7 , 32 ].…”

Section: Discussionmentioning

confidence: 98%

Early Outcomes of Percutaneous Pulmonary Valve Implantation with Pulsta and Melody Valves: The First Report from Korea

Kim

Jung

et al. 2020

JCM

View full text Add to dashboard Cite

Percutaneous pulmonary valve implantation (PPVI) is used to treat pulmonary stenosis (PS) or pulmonary regurgitation (PR). We described our experience with PPVI, specifically valve-in-valve transcatheter pulmonary valve replacement using the Melody valve and novel self-expandable systems using the Pulsta valve. We reviewed data from 42 patients undergoing PPVI. Twenty-nine patients had Melody valves in mostly bioprosthetic valves, valved conduits, and homografts in the pulmonary position. Following Melody valve implantation, the peak right ventricle-to-pulmonary artery gradient decreased from 51.3 ± 11.5 to 16.7 ± 3.3 mmHg and right ventricular systolic pressure fell from 70.0 ± 16.8 to 41.3 ± 17.8 mmHg. Thirteen patients with native right ventricular outflow tract (RVOT) lesions and homograft underwent PPVI with the new self-expandable Pulsta valve—a nitinol wire stent mounted with a trileaflet porcine pericardial valve. Following Pulsta valve implantation, cardiac magnetic resonance imaging showed a decreased PR fraction and that the right ventricular end-diastolic volume index decreased from 166.1 ± 11.9 to 123.6 ± 12.4 mL/m2. There were no mortality, severe procedural morbidity, or valve-related complications. At the mean 14.2 month (4–57 months) follow-up, no patients had more than mild PR. PPVI using Melody and Pulsta valves was first shown to provide excellent early outcomes without serious adverse event in most patients with RVOT dysfunction in Korea.

show abstract

“…13,19 Mortality is a rare occurrence with a reported rate of 0.2% to 0.8%. 20 Implantation is aborted in up to 10% of patients due to coronary and/or aortic compression. Noninvasive imaging techniques are anticipated that will better predict the compliance of the landing zone as well as coronary and aortic compression.…”

Section: Central Messagementioning

confidence: 99%

Transcatheter pulmonary valve replacement in native and nonconduit right ventricle outflow tracts

Tannous¹,

Nugent²

2021

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

Feature Editor's Introduction-Only 2 years ago, I wrote an editorial about transcatheter pulmonary valve insertion and commented that this was a, new paradigm. 1 Successful transcatheter pulmonary valve insertion had been reported in 100 patients where the previous surgically placed bioprosthetic pulmonary valve was used as a landing zone. 2 This Invited Expert Opinion provides a perspective on the following paper:

show abstract

Adverse Events, Radiation Exposure, and Reinterventions Following Transcatheter Pulmonary Valve Replacement

Cited by 26 publications

References 27 publications

Outcomes of Transcatheter Pulmonary Valve Replacement and Surgical Pulmonary Valve Replacement: A Cohort Analysis

Outcomes of Transcatheter Pulmonary Valve Replacement and Surgical Pulmonary Valve Replacement: A Cohort Analysis

Early Outcomes of Percutaneous Pulmonary Valve Implantation with Pulsta and Melody Valves: The First Report from Korea

Transcatheter pulmonary valve replacement in native and nonconduit right ventricle outflow tracts

Contact Info

Product

Resources

About